Back to Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 1

Rasagiline in treatment of Parkinson’s disease

Authors Nayak L, Henchcliffe C

Published 8 February 2008 Volume 2008:4(1) Pages 11—20

DOI https://doi.org/10.2147/NDT.S464


Lakshmi Nayak1, Claire Henchcliffe2

1Department of Neurology; 2Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, USA

Abstract: Rasagiline (N-propargyl-1 (R)-aminoindan) is a novel propargylamine, irreversible, selective monoamine oxidase inhibitor for treatment of Parkinson’s disease (PD), a progressive condition associated with degeneration of dopaminergic neurons in the substantia nigra. Rasagiline inhibits striatal dopamine metabolism, thereby providing relief from motor symptoms of PD. It may be dosed once daily and, unlike selegiline, it is metabolized to non-amphetamine compounds. In a large clinical trial, rasagiline has proved effective, safe, and well tolerated in early PD as monotherapy. In two phase III clinical trials in advanced PD with motor fluctuations, rasagiline as an adjunct to levodopa significantly decreases “off” time. In animal models of PD, data supports a neuroprotective effect of rasagiline, and its active metabolite aminoindan. Analysis of delayed-start clinical trial suggests the potential for disease modification, and further trials are examining this effect.

Keywords: rasagiline, monoamine oxidase inhibitor, propargylamine, Parkinson’s disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]